Integra LifeSciences (NASDAQ:IART) Stock Price Crosses Above 200 Day Moving Average – Time to Sell?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $14.94 and traded as high as $16.21. Integra LifeSciences shares last traded at $16.12, with a volume of 539,025 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on IART shares. Wall Street Zen lowered shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. UBS Group initiated coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price on the stock. Wells Fargo & Company lifted their target price on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. BMO Capital Markets initiated coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. Finally, Truist Financial upped their price target on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Stock Performance

The business has a 50-day moving average of $17.03 and a 200 day moving average of $14.94. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The company has a market cap of $1.25 billion, a PE ratio of -179.09, a PEG ratio of 0.83 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The business had revenue of $418.76 million for the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Large investors have recently added to or reduced their stakes in the business. Paradigm Capital Management Inc. NY raised its position in Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after acquiring an additional 1,347,700 shares during the period. Wellington Management Group LLP grew its position in shares of Integra LifeSciences by 12.4% during the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after acquiring an additional 160,814 shares during the period. Bank of America Corp DE increased its stake in shares of Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares in the last quarter. Invenomic Capital Management LP increased its stake in shares of Integra LifeSciences by 78.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after purchasing an additional 463,729 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its holdings in Integra LifeSciences by 27.4% in the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after purchasing an additional 211,774 shares during the period. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company’s portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.